Clinical effects of a continuous glucose monitoring (CGM) system for the glycemic control in patients with type 2 diabetes and acute illness or post-operation period

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CRIS

Registry ID

KCT0011219

Enrollment

Registered

2025-11-26

Start date

2025-10-22

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Participants will have a CGM device attached, and the study investigators will manage blood glucose according to the institution’s standard glucose control protocol, using both CGM re

instead, the medical staff will perform daily real-time glucose monitoring throughout hospitalization, adjusting glucose levels based on both CGM and POC (preprandial and bedtime) glucose values. Diff

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants must meet all of the following criteria to be eligible for the study: Adults aged 19 years or older diagnosed with type 2 diabetes mellitus. Currently hospitalized due to an acute medical illness or for a planned (elective) surgery. Willing and able to wear a continuous glucose monitoring (CGM) device during the study period. Voluntarily agree to participate in the clinical trial, with written informed consent obtained from the participant or a legally authorized representative. Expected hospital stay of at least 7 days. Requires basal-bolus insulin therapy or insulin pump therapy as part of diabetes management during hospitalization.

Exclusion criteria

Exclusion criteria: Participants meeting any of the following criteria will be excluded from the study: Diagnosis of type 1 diabetes mellitus. Pregnant or breastfeeding women. Individuals with severe psychiatric disorders or significant cognitive impairment that may affect study participation. Organ transplant recipients or individuals requiring long-term immunosuppressive therapy. Participation in another clinical trial within 30 days prior to screening (excluding observational studies). Current use of high-dose ascorbic acid (>500 mg/day). Patients on dialysis or requiring dialysis during the study period. Hospice care patients or those with a life expectancy of less than 72 hours. Any condition or circumstance that, in the investigator’s judgment, makes the patient unsuitable for participation in the clinical trial.

Design outcomes

Primary

Measure	Time frame
Difference in TIR (%)	—

Secondary

Measure	Time frame
Differences in TAR >180mg/dL (%) and TAR >250mg/dL (%)	—

Countries

Korea, Republic of

Contacts

Public ContactSeung-Hyun Ko

The Catholic University of Korea, Songeui Campus

kosh@catholic.ac.kr+82-31-249-8059

Outcome results